-
公开(公告)号：US20230094773A1
公开(公告)日：2023-03-30
申请号：US17825430
申请日：2022-05-26
发明人： Norihito Nakata , Nobuya Kobashi , Yoshinari Shoyama , Mitsuhiro Matono , Yasushi Ochiai , Takayuki Murakami
摘要： The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits α particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
-
公开(公告)号：US11369701B2
公开(公告)日：2022-06-28
申请号：US17367077
申请日：2021-07-02
发明人： Norihito Nakata , Nobuya Kobashi , Yoshinari Shoyama , Mitsuhiro Matono , Yasushi Ochiai , Takayuki Murakami
摘要： The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits α particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
-
公开(公告)号：US11701440B2
公开(公告)日：2023-07-18
申请号：US17047859
申请日：2019-04-15
申请人： NIHON MEDI-PHYSICS CO., LTD. , National University Corporation Kagoshima University , National University Corporation Chiba University
发明人： Shota Komoto , Yu Ogawa , Yoshinari Shoyama , Tadashi Hatano , Yuji Ito , Yasushi Arano , Hiroyuki Suzuki , Tomoya Uehara
IPC分类号： A61K47/68 , A61K51/10 , C07K5/065 , C07K5/087 , A61K51/04 , A61K51/08 , C07D257/02 , C07K7/08 , C07K16/32
CPC分类号： A61K51/1093 , A61K47/6887 , A61K47/6889 , A61K51/0482 , A61K51/088 , A61K51/1096 , C07D257/02 , C07K5/06078 , C07K5/0812 , C07K7/08 , C07K16/32 , C07K2317/21
摘要： Described is a labeling technique which can facilitate the metabolism in the liver after administration to patients without the reduction in the antibody function, thereby reducing accumulation of radionuclides in an organ such as the liver, and a modified antibody containing an IgG antibody and an IgG-binding peptide bound to the IgG antibody. The IgG-binding peptide has an amino acid sequence consisting of 13 to 17 amino acid residues, such as GPDCAYH(Xaa1)GELVWCTFH (SEQ ID NO: 2) wherein Xaa1 represents a lysine residue, a cysteine residue, an aspartic acid residue, a glutamic acid residue, 2-aminosuberic acid, or diaminopropionic acid, and a compound represented by the following formula (II-1) is linked at a position of the lysine residue via a modification linker to the N terminus of the IgG-binding peptide.
-
公开(公告)号：US20210338852A1
公开(公告)日：2021-11-04
申请号：US17367077
申请日：2021-07-02
发明人： Norihito Nakata , Nobuya Kobashi , Yoshinari Shoyama , Mitsuhiro Matono , Yasushi Ochiai , Takayuki Murakami
摘要： The RI-labeled anti-MUC5AC humanized antibody of the present invention is a conjugate of a chelating agent chelated with a radionuclide and an antibody (the radionuclide is a metal nuclide that emits α particle or positron, and the antibody is a humanized antibody specifically binding to MUC5AC), and is superior in specificity for MUC5AC and accumulation in tumor. Therefore, it is extremely useful for the treatment and/or diagnosis of diseases in which MUC5AC is overexpressed, particularly cancer.
-
-
-
搜索结果
4 条记录 (耗时 0.023 秒)
